Pharmacology of the Neurotransmitter Release Enhancer Linopirdine (DuP 996), and Insights into Its Mechanism of Action

Advances in Pharmacology

Volumn 35, Issue C, 1996, Pages 349-384

  Aiken, Simon P ^a   Zaczek, Robert ^b   Brown, Barry S ^c  

^a ASTRAZENECA   (United Kingdom)

^b Departments of Central Nervous System Diseases Research

^c DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLE DERIVATIVE; LINOPIRDINE; PYRIDINE DERIVATIVE;

ALZHEIMER DISEASE; CHEMISTRY; DRUG INTERACTION; ELECTROPHYSIOLOGY; METABOLISM; REVIEW;

ALZHEIMER DISEASE; DRUG INTERACTIONS; ELECTROPHYSIOLOGY; INDOLES; PYRIDINES;

EID: 0029682660     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60281-1     Document Type: Article

References (84)

1. Aiken S.P., and Brown B.S. Linopirdine (DuP 996), a neurotransmitter release enhancer, blocks M-current in rat CA1 hippocampal neurons. Biophys. J. 66 (1994) A210
2. Aiken S.P., Lampe B.J., Murphy P.A., and Brown B.S. Reduction of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer. Br. J. Pharmacol. 115 (1995) 1163-1168
3. Alberici G.P., Cook L., Gaskill J.-L., and Steinfels G.F. The electroencephalographic (EEG) effects of DuP 996, a compound with cognitive enhancing properties. Soc. Neurosci. Abstr. 17 (1991) 1588
4. + channels. Science 247 (1990) 852-854
5. Baxter M.G., Rohrbach K.W., Tarn S.W., Zaczek R., Frick K.M., Golski S., Wan R.-Q., and Olton D.S. Effects of linopirdine (DuP 996) and X9121 on age-related memory impairments and on the cholinergic system. Drug Dev. Res. 31 (1994) 186-196
6. Baxter M.G., Rohrbach K.W., Tam S.W., Zaczek R., and Olton D.S. Effects of linopirdine and DuP 921 on age-related impairments in memory and on the cholinergic system. Soc. Neurosci. Abstr. 19 (1993) 1041
7. Benardo L.S., and Prince D.A. Ionic mechanisms of cholinergic excitation in mammalian hippocampal pyramidal cells. Brain Res. 249 (1982) 333-344
8. Benson D.M., Blitzer R.D., and Landau E.M. An analysis of the depolarization produced in guinea-pig hippocampus by cholinergic receptor stimulation. J. Physiol. (London) 404 (1988) 479-496
9. Bernard V., Dumartin B., Lamy E., and Bloch B. Fos immunoreactivity after stimulation or inhibition of muscarinic receptors indicates anatomical specificity for cholinergic control of striatal efferent neurons and cortical neurons in the rat. Eur. J. Neurosci. 5 (1993) 1218-1225
10. 3H]norepi-nephrine release from synaptosomes is blocked by depolarization. J. Pharmacol. Exp. Ther. 253 (1990) 1063-1069
11. Brioni J.D., Curzon P., Buckley M.J., Arneric S.P., and Decker M.W. Linopirdine (DuP996) facilitates the retention of avoidance training and improves performance of septal-lesioned rats in the water maze. Pharmacol. Biochetn. Behav. 44 (1993) 37-43
12. Brown D. M-currents: an update. Trends Neurosci. 11 (1988) 294-299
13. + current in a vertebrate neurone. Nature (London) 283 (1980) 673-676
14. Choi O.H., Shamim M.T., Padgett W.L., and Daly J.W. Caffeine and theophylline analogues: correlation of behavioral effects with activity as adenosine receptor antagonists and as phosphodiesterase inhibitors. Life Set. 43 (1988) 387-398
15. Cook L., Nickolson V.J., Steinfels G.F., Rohrbach K.W., and DeNoble V.J. Cognition enhancement by the acetylcholine releaser DuP 996. Drug Dev. Res. 19 (1990) 301-314
16. Cross A.J., Crow T.J., Perry E.K., Perry R.H., Blessed G., and Tomlinson B.E. Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br. Med. J. 282 (1981) 93-94
17. Daly J.W., Butts-Lamb P., and Padgett W. Subclasses of adenosine receptors in the cortical nervous system: interaction with caffeine and related methylxanthines. Cell Mol. Neurobiol. 3 (1984) 69-80
18. Davidson M., and Stern R.G. The treatment of cognitive impairment in Alzheimer's disease: beyond the cholinergic approach. Psychiatr. Clin. North Am. 14 (1991) 461-482
19. Davies P., and Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet ii (1976) 1403
20. DeNoble V.J., DeNoble K.F., Spencer K.R., Johnson L.C., Cook L., Myers M.J., and Scribner R.M. Comparison of DuP 996, with physostigmine, THA and 3,4-DAP on hypoxia-induced amnesia in rats. Pharmacol. Biochem. Behav. 36 (1990) 957-961
21. Dent G.W., Rule B.L., Tam S.W., and De Souza E.B. Effects of the memory enhancer linopirdine (Dup 996) on cerebral glucose metabolism in naive and hypoxia-exposed rats. Brain Res. 620 (1993) 7-15
22. Dent G., Tam S.W., and Grzanna R. The memory enhancer linopirdine increases c-fos expression in cerebral cortex of aged rats. Soc. Neurosci. Abstr: 19 (1993) 1040
23. De Souza E.B. Preclinical strategies for symptomatic treatment of cognitive deficits seen in Alzheimer's disease: focus on cholinergic mechanisms. In: Corain B., Iqbal K., Nicolini M., Winblad B., Wisniewski H., and Zatta P. (Eds). "Alzheimer's Disease: Advances in Clinical and Basic Research" (1993), Wiley, Chichester. 539-548
24. 3H]DuP 996 labels a novel binding site in rat brain involved in the enhancement of stimulus-induced acetylcholine, dopamine and serotonin release: autoradiographic localization studies. Soc. Neurosci. Abstr. 17 (1991) 1588
25. Dutar P., and Nicoll R.A. Classification of muscarinic responses in hippocampus in terms of receptor subtypes and second-messenger systems: electrophysiological studies in vitro. J. Neurosci. 8 (1988) 4214-4224
26. Earl R.A., Myers M.J., Johnson A.L., Scribner R.M., Wuonola M.A., Boswell G.A., Wilkerson W.W., Nickolson V.J., Tam S.W., Brittelli D.R., Chorvat R.J., Zaczek R., Cook L., Wang C., Zhang X., Lan R., Mi B., and Wenting H. Acetylcholine-releasing agents as cognition enhancers. Structure-activity relationships of pyridinyl pendant groups on selected core structures. Bioorg. Med. Chem. Lett. 2 (1992) 851-854
27. Ernst R.L., and Hay J.W. The US economic and social costs of Alzheimer's disease revisited. Am. J. Public Health 84 (1994) 1261-1264
28. Fairhurst A.S., Whittaker M.L., and Ehlert F.J. Interactions of D600 (methoxyvera-pamil) and local anesthetics with rat brain α-adrenergic and muscarinic receptors. Bio-chem. Pharmacol. 29 (1980) 155-162
29. Frey J.M., Murphy P.A., and Brown B.S. DuP 996, a novel neurotransmitter releaser, blocks voltage-activated potassium currents in cultured neocortical neurons. Soc. Neurosci. Abstr. 17 (1991) 1588
30. Gottfries C.G. Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment. Pyschopharmacology 86 (1985) 245-252
31. Griffith W.H. Membrane properties of cell types within guinea pig basal forebrain nuclei in vitro. J. Neurophys. 59 (1988) 1590-1612
32. Hepler D.J., Wenk G.L., Cribbs B.L., Olton D.S., and Coyle J.T. Memory impairments following basal forebrain lesions. Brain Res. 346 (1985) 8-14
33. Huger F.P., Smith C.P., Petko W.W., Conway P.G., Effland R.C., and Klein J.T. HP 749, a potential therapeutic agent for Alzheimer's disease: (II) Neurochemical profile. Soc. Neurosci. Abstr. 16 (1990) 612
34. Hughes P., and Dragunow M. Muscarinic receptor-mediated induction of Fos protein in rat brain. Neurosci. Lett. 150 (1993) 122-126
35. Jacobs E.R., and DeCoursey T.E. Mechanisms of potassium channel block in rat alveolar epithelial cells. J. Pharmacol. Exp. Ther:. 255 (1990) 459-472
36. Kishida H., Yamamoto K., Fuse Y., Noda M., and Higashida H. A quinuclidine derivative induces an inward current associated with M-potassium current inhibition in ml-muscarinic receptor-transformed NG108-15 cells. Soc. Neurosci. Abstr. 21 (1995) 2039
37. K|m) in rat sympathetic neurones by linopirdine (DuP996). Br. J. Pharmacol. 116 (1995) 123P
38. Lampe B.W., and Brown B.S. Electrophysiological effects of DuP 996 on hippocampal CA1 neurons. Soc. Neurosci. Abstr. 17 (1991) 1588
39. Lancaster B., and Nicoll R.A. Properties of two calcium-activated hyperpolarizations in rat hippocampal neurones. J. Physiol. {London) 389 (1987) 187-204
40. + ion permeabilities in the acetylcholine release enhancing effects of linopirdine (DuP 996) in rat cerebral cortical slices. J. Pharmacol. Exp. Ther. 271 (1994) 891-897
41. Madison D.V., and Nicoll R.A. Control of repetitive discharge of rat CA1 pyramidal neurones in vitro. J. Physiol. (London) 354 (1984) 319-331
42. Marsh S.J., Hubbard A., and Brown D.A. Some actions of 9-amino-l,2,3,4-tetrahydroacridine (THA) on cholinergic transmission and membrane currents in rat sympathetic ganglia. Eur. J. Neurosci. 2 (1990) 1127-1134
43. Marynowski M., Maciag C., Rominger C.M., Rominger D., Tam S.W., and Zaczek R. Effects of linopirdine (DuP 996) on hippocampal extracellular levels of acetylcholine in freely moving animals. Soc. Neurosci. Abstr. 19 (1993) 1040
44. McKinney M., and Coyle J.T. The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease. Mayo Clin. Proc. 66 (1991) 1225-1237
45. McPherson P.S., Kim Y.K., Valdivia H., Knudson C.M., Takekura H., Franzini A.C., Coronado R., and Campbell K.P. The brain ryanodine receptor: a caffeine-sensitive calcium release channel. Neuron 7 (1991) 17-25
46. Murphy P.A., and Brown B.S. Role of synaptic transmission and chloride conductance in the electrophysiological effects of linopirdine on CA1 hippocampal neurons in vitro. Soc. Neurosci. Abstr. 18 (1992) 1354
47. Nickolson V.J., Tam S.W., Meyers M.J., and Cook L. DuP 996 (3,3-bis(4-pyrindinylmethyl)-l-phenylindolin-2-one) enhances the stimulus-induced release of acetylcholine from rat brain in vitro and in vivo. Drug Dev. Res. 19 (1990) 285-300
48. Olton D.S., Givens B.S., Markowska A.L., Shapiro M., and Golski S. Mnemonic functions of the cholinergic septohippocampal system. In: Squire L.R., Weinberger N.M., Lynch G., and McGaugh J.L. (Eds). "Memory: Organization and Locus of Change" (1991) 250-269
49. Pappone P.A., and Ortiz-Miranda S.I. Blockers of voltage-gated K channels inhibit proliferation of cultured brown fat cells. Am. J. Physiol. 264 (1993) C1014-C1019
50. 2+ transients, but these events do not explain M-current suppression. Neuron 1 (1988) 477-484
51. 3H]acetylcholine release from rat hippocampal slices. J. Pharmacol. Exp. Ther. 244 (1988) 213-217
52. Provan S.D., and Miyamoto M.D. Effect of the putative cognitive enhancer, linopirdine (DuP 996), on quantal parameters of acetylcholine release at the frog neuromuscular junction. Br. J. Pharmacol. 111 (1994) 1103-1110
53. Pulsinelli W.A., and Duffy T.E. Local cerebral glucose metabolism during controlled hypoxemia in rats. Science 204 (1979) 626-629
54. Robbins J., Trouslard J., Marsh S.J., and Brown D.A. Kinetic and pharmacological properties of the M-current in rodent neuroblastoma X glioma hybrid cells. J. Physiol. (London) 451 (1992) 159-185
55. Robitaille R., Garcia M.L., Kaczorowski G.J., and Charlton M.P. Functional colocalization of calcium and calcium-gated potassium channels in control of transmitter release. Neuron 11 (1993) 645-655
56. 3H]DuP 996 labels a novel receptor site involved in enhancement of stimulus-induced acetylcholine, dopamine and serotonin release. Soc. Neurosci. Abstr. 17 (1991) 1588
57. Saint D.A. The effects of 4-aminopyridine and tetraethylammonium on the kinetics of transmitter release at the mammalian neuromuscular synapse. Can. J. Physiol. Pharmacol. 67 (1989) 1045-1050
58. Saletu B., Darragh A., Breuel H.P., Herrmann W., Salmon P., Coen R., and Anderer P. EEG mapping central effects of multiple doses of linopirine-a cognitive enhancer-in healthy elderly male subjects. Hum. Psychopharmacol. 6 (1991) 267-275
59. Saletu B., Darragh A., Salmon P., and Coen R. EEG brain mapping in evaluating the time-course of the central action of DUP 996-a new acetylcholine releasing drug. Br. J. Clin. Pharmacol. 28 (1989) 1-16
60. Sarter M. Taking stock of cognition enhancers. Trends Pharm. Sci. 12 (1991) 456-461
61. Saydoff J.A., and Zaczek R. Linopirdine (DuP996) enhances KC1 evoked, but not basal, release of endogenous dopamine from superfused rat striatal slices. FASEB J. 7 (1993) A263
62. 2+ stores on KC1 evoked acetylcholine release and linopirdine (DuP 996) release enhancement in rat hippocampal slices. Soc. Neurosci. Abstr. 19 (1993) 1041
63. Schäfer S., Béhé P., and Meves H. Inhibition of the M current in NG108-15 neuroblastoma X glioma hybrid cells. Pflügers Arch. 418 (1991) 581-591
64. Schnee M.E., and Brown B.S. Linopirdine, a neurotransmitter release enhancer, blocks voltage-activated potassium currents in hippocampal neurons. Soc. Neurosci. Abstr. 21 (1995) 1832
65. Smith C.P., Brougham L.R., and Vargas H.M. Linopirdine (DuP 996) selectively enhances acetylcholine release induced by high potassium, but not electrical stimulation, in rat brain slices and guinea pig ileum. Drug Dev. Res. 29 (1993) 262-270
66. Smith T.M., Ramirez A.D., Heck S.D., Jasys V.J., Volkmann R.A., Forman J.T., and Liston D.R. In vivo microdialysis and pharmacokinetic studies with DuP-996. Soc. Neurosci. Abstr. 19 (1993) 1041
67. Storm J.F. Potassium currents in hippocampal pyramidal cells. In: Storm-Mathisen J., Zimmer J., and Ottersen O.P. (Eds). "Progress in Brain Research" 83 (1990), Elsevier, Amsterdam. 161-187
68. Summers W.K., Majovski L.V., Marsh G.M., Tachiki K., and Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N. Engl. J. Med. 315 (1986) 1241-1245
69. Tam S.W., Rominger D., and Nickolson V.J. Novel receptor site involved in enhancement of stimulus-induced acetylcholine, dopamine, and serotonin release. Mol. Pharmacol. 40 (1991) 16-21
70. 2+-ATPase. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 2466-2470
71. Thomine S., Zimmermann S., VanDuijn B., Barbier-Brygoo H., and Guern J. Calcium channel antagonists induce direct inhibition of the outward rectifying potassium channel in tobacco protoplasts. FEBS Lett. 340 (1994) 45-50
72. 2+-dependent release of glutamate from guinea-pig cerebrocortical synaptosomes. J. Neurochem. 52 (1989) 201-206
73. Tsai M.-C., Su J.-L., Chen M.-L., Fan S.-Z., and Cheng C.-Y. The effect of 3,3-dipyridylmethyl-1-phenyl-2-indolinone on the neuromuscular transmission in the rodent skeletal muscles. Neuropharmacology 31 (1992) 89-94
74. van Dyck C.H., Lin C.H., Robinson R., Cellar J., Narayan M., Arnsten A.F.T., and Hoffer P.B. Effects of the acetylcholine releaser linopirdine on SPECT rCBF and cognitive function in Alzheimer's disease. Soc. Heurosci. Abstr. 21 (1995) 1976
75. Vickroy T.W. Presynaptic cholinergic actions by the putative cognitive enhancing agent DuP 996. J. Pharmacol. Exp. Ther. 264 (1993) 910-917
76. Vogél-Scibilia S., and Gershon S. An update on cognitive enhancers for the elderly. New Trends Clin. Neuropharmacol. III (1989) 207-216
77. Wesseling H., Agoston S., VanDam G.B.P., Pasma J., Wit D.J., and Havinga H. Effects of 4-aminopyridine in elderly patients with Alzheimers's disease. N. Engl. J. Med. 310 (1984) 988-989
78. Winkler J., Suhr S.T., Gage F.H., Thai L.J., and Fisher L.J. Essential role of neocortical acetylcholine in spatial memory. Nature (London) 375 (1995) 484-487
79. Zaczek R., Chorvat R.J., Earl R.A., and Tam S.W. Neurotransmitter release enhancement as a possible therapy for neurodegenerative diseases: update on linopirdine (DuP996). In: Giacobini E., and Becker R. (Eds). "Alzheimer Disease: Therapeutic Strategies" (1994), Birkäuser, Boston. 252-255
80. Zaczek R., Rohrbach K.W., Tam S.W., and Cook L. Preclinical evaluation of linopirdine: neurochemical and behavioral effects. In: Hanin I., Yoshida M., and Fisher A. (Eds). "Alzheimer's and Parkinson's Diseases: Recent Developments" (1995), Plenum, New York. 491-498
81. Zaczek R., and Saydoff J. Depolarization activated releasers of transmitters as therapeutics for dementia: preclinical characterization of linopirdine (DuP 996). Curr. Opin. Invest. Drugs 2 (1993) 1097-1104
82. Zaczek R., Tinker W.J., Logue A.R., Cain G.A., Teleha C.A., and Tam S.W. Effects of linopirdine, HP 749, and glycyl-prolyl-glutamate on transmitter release and uptake. Drug Dev. Res. 29 (1993) 203-208
83. 3H]acetylcholine from superfused brain slices. Soc. Neurosci. Abstr. 19 (1993) 1040
84. Zaczek R., Tinker W.J., and Tam S.W. Unique properties of norepinephrine release from terminals arising from the locus coeruleus: high potassium sensitivity and lack of linopirdine (DuP 996) enhancement. Neurosci. Lett. 155 (1993) 107-111